alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Data Provided by FEMA on Emergency Transportable Housing Units By Type of Site

CY Disaster

Private Sites Provided

By Occupant

Commercial Sites 

Leased from Private Entities

Group Sites 

Constructed by FEMA All Sites

Units UFAS UFAS % Units UFAS UFAS % Units UFAS UFAS % Units UFAS UFAS %

2008 1744 20 4 20.0% 1 0 0% - - - 21 4 19.0%

1745 35 0 0% 3 0 0% - - - 38 0 0%

1763 76 30 39.5% 507 63 12.4% - - - 583 93 16.0%

1766 1 1 1 1 1 1 1 1 180 7 8.8%

1771 1 1 1 1 1 1 1 1 123 3 13.0%

1786 92 16 17.4% 152 23 15.1% - - - 244 39 16.0%

1791 3,328 298 9.0% 208 29 13.9% 134 18 13.4% 3,670 345 9.4%

1792 156 26 16.7% 228 39 17.1% - - - 384 65 16.9%

2009 1834 5 0 0% 25 5 20.0% - - - 30 5 16.7%

1838 27 0 0% 58 1 1.7% 53 3 5.7% 138 4 2.9%

2010 1906 11 1 9.1% 13 1 7.7% - - - 24 2 8.3%

1918 1 0 0% 16 0 0% - - - 17 0 0%

2011 1969 30 6 20.0% 6 1 16.7% - - - 36 7 19.4%

1971 235 25 10.6% 72 6 8.3% - - - 307 31 10.1%

1972 65 11 16.9% 16 2 12.5% - - - 81 13 16.0%

1975 49 3 6.1% - - - - - - 49 3 6.1%

1980 - - - 145 15 10.3% 432 37 8.6% 577 52 9.0%

1981 1,098 13 1.2% 308 47 15.3% 666 73 11.0% 2,072 133 6.4%

1983 4 0 0% 52 4 7.7% - - - 56 4 7.1%

4019 162 75 46.3% 19 10 52.6% 53 3 5.7% 234 88 37.6%

4020 22 3 13.6% 27 5 18.5% - - - 49 8 16.3%

4029 82 46 56.1% - - - - - - 82 46 56.1%

4030 35 7 20.0% 191 15 7.9% 57 1 1.8% 283 23 8.1%

4031 33 5 15.2% 45 2 4.4% - - - 78 7 9.0%

2012 4080 1 0 0% 31 2 6.5% - - - 32 2 6.3%

4086 1 0 0% 81 3 3.7% - -- 82 3 3.7%

2013 4145 - - - 54 4 7.4% - - - 54 4 7.4%

Totals 5,568 569 10.2% 2,258 277 12.3% 1,395 135 9.7% 9,324 991 10.6%

1 Data not available by type of site on which units were installed.
# C_2016156EN.01003501.xml

| 2.5.2016 | EN | Official Journal of the European Union | C 156/35 |
| --- | --- | --- | --- |

2.5.2016

EN

Official Journal of the European Union

C 156/35

---

Judgment of the General Court of 16 March 2016 — The Body Shop International v OHIM — Spa Monopole (SPA WISDOM)

(Case T-201/14) (1)

1

((Community trade mark - Opposition proceedings - Application for the Community word mark SPA WISDOM - Earlier Benelux word mark SPA - Relative grounds for refusal - Unfair advantage taken of the distinctive character or the repute of the earlier trade mark - Article 8(5) of Regulation (EC) No 207/2009))

(2016/C 156/45)

Language of the case: English

Parties

Parties

Applicant: The Body Shop International plc (Littlehampton, United Kingdom) (represented by: I. Vernimme, H. Viaene, S. Vandewynckel and D. Gillet, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: J. Crespo Carrillo, acting as Agent)

Defendant:

Other party to the proceedings before the Board of Appeal of OHIM, intervener before the General Court: Spa Monopole, compagnie fermière de Spa SA/NV (Spa, Belgium) (represented by: E. Cornu and E. De Gryse, lawyers)

Other party to the proceedings before the Board of Appeal of OHIM, intervener before the General Court:

Re:

Re:

Action brought against the decision of the Fourth Board of Appeal of OHIM of 16 January 2014 (Case R 1516/2012-4), relating to opposition proceedings between The Body Shop International plc and Spa Monopole, compagnie fermière de Spa SA/NV.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders The Body Shop International plc to pay the costs. |
| --- | --- |

2.

Orders The Body Shop International plc to pay the costs.

---

(1)  OJ C 235, 21.7.2014.

1

---
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.4660 Skin marker. ( a ) *Identification.* A skin marker is a pen-like device intended to be used to write on the patient's skin, e.g., to outline surgical incision sites or mark anatomical sites for accurate blood pressure measurement.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.
[53 FR 23872, June 24, 1988, as amended at 59 FR 63010, Dec. 7, 1994; 66 FR 38803, July 25, 2001]
EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of
Evergreen Solar, Inc. (the Company) on Form 10-K for the period ended December 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Michael El-Hillow, Chief Executive Officer
of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



|                                         
|-----------------------------------------
|                                         
|/s/    Michael
El-Hillow                 
|Michael El-Hillow
Chief Executive Officer
|March 9, 2011                            

This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company
under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and
furnished to the Securities and Exchange Commission or its staff upon request.
# C_2015026EN.01001901.xml

| 26.1.2015 | EN | Official Journal of the European Union | C 26/19 |
| --- | --- | --- | --- |

26.1.2015

EN

Official Journal of the European Union

C 26/19

---

Request for a preliminary ruling from the Verwaltungsgericht Berlin (Germany) lodged on 21 November 2014 — Ukamaka Mary Jecinta Oruche and Nzubechukwu Emmanuel Oruche v Bundesrepublik Deutschland

(Case C-527/14)

(2015/C 026/22)

Language of the case: German

Referring court

Referring court

Verwaltungsgericht Berlin

Parties to the main proceedings

Parties to the main proceedings

Applicants: Ukamaka Mary Jecinta Oruche and Nzubechukwu Emmanuel Oruche

Applicants:

Defendant: Bundesrepublik Deutschland

Defendant:

Other parties: Oberbürgermeister der Stadt Potsdam, Emeka Emmanuel Mary Oruche

Other parties

Question referred

Question referred

Should the first subparagraph of Article 7(2) of Council Directive 2003/86/EC of 22 September 2003 on the right to family reunification (1) be interpreted as precluding a provision of national law which makes the first entry of a member of the family of a sponsor conditional on the requirement that, prior to entry, the family member can demonstrate the ability to communicate, in a basic way, in the German language?

1

---

(1)  OJ 2003 L 251, p. 12.

1

---
<PAGE>   1

                       [THE LOEWEN GROUP INC. LETTERHEAD]

(NYSE, TSE, ME: LWN) 
     NEWS


Contact:
Thomas C. Franco
Broadgate Consultants, Inc.
Tel: (212) 232-2222






                     LOEWEN GROUP ANNOUNCES CASH DIVIDEND ON

                                PREFERRED SHARES

          -------------------------------------------------------------

VANCOUVER, BC, November 23, 1998 -- The Loewen Group Inc. (NYSE, TSE, ME: LWN)
announced today that the scheduled quarterly cash dividend of Cdn. $0.375 per
share on the Company's 6% Cumulative Redeemable Convertible First Preferred
Shares, Series C has been declared payable on January 4, 1999 to shareholders of
record on December 22, 1998. It is expected that the preferred shares will begin
trading ex-dividend on December 18, 1998.

The Loewen Group Inc. is the second largest funeral home and cemetery operator
in North America. The Company employs approximately 16,000 people and owns or
operates more than 1,100 funeral homes and over 500 cemeteries across the United
States, Canada and the United Kingdom. Over 90 percent of the Company's revenue
is derived from the United States.

The Loewen Group's website is located at http://www.loewengroup.com

                                      # # #
Editorial Note on Part 570
Editorial Note: Nomenclature changes to part appear at 88 FR 45066, July 14, 2023.

§ 570.35 Affirmation of generally recognized as safe (GRAS) status. ( a ) The Commissioner, on his own initiative, may affirm that a substance that directly or indirectly becomes a component of food is GRAS under the conditions of its intended use.
( b ) ( 1 ) If the Commissioner proposes on his own initiative that a substance is entitled to affirmation as GRAS under the conditions of its intended use, he will place all of the data and information on which he relies on public file in the office of the Dockets Management Staff and will publish in the Federal Register a notice giving the name of the substance, its proposed uses, and any limitations proposed for purposes other than safety.
( 2 ) The Federal Register notice will allow a period of 60 days during which any interested person may review the data and information and/or file comments with the Dockets Management Staff. Copies of all comments received shall be made available for examination in the Dockets Management Staff's office.
( 3 ) The Commissioner will evaluate all comments received. If he concludes that there is convincing evidence that the substance is GRAS under the conditions of its intended use as described in § 570.30, he will publish a notice in the Federal Register listing the GRAS conditions of use in this subchapter E.
( 4 ) If, after evaluation of the comments, the Commissioner concludes that there is a lack of convincing evidence that the substance is GRAS under the conditions of its intended use and that it should be considered a food additive subject to section 409 of the Federal Food, Drug, and Cosmetic Act, he shall publish a notice thereof in the Federal Register in accordance with § 570.38.
[41 FR 38644, Sept. 10, 1976, as amended at 42 FR 4717, Jan. 25, 1977; 42 FR 15675, Mar. 22, 1977; 42 FR 55207, Oct. 10, 1977; 50 FR 7517, Feb. 22, 1985; 50 FR 16668, Apr. 26, 1985; 54 FR 18281, Apr. 28, 1989; 62 FR 40600, July 29, 1997; 81 FR 55052, Aug. 17, 2016; 88 FR 45066, July 14, 2023]
# C_2015262EN.01004403.xml

| 10.8.2015 | EN | Official Journal of the European Union | C 262/44 |
| --- | --- | --- | --- |

10.8.2015

EN

Official Journal of the European Union

C 262/44

---

Order of the Civil Service Tribunal of 30 June 2015 — EI v Council

(Case F-87/14) (1)

1

(2015/C 262/62)

Language of the case: French

The President of the Third Chamber has ordered that the case be removed from the register.

---

(1)  OJ C 431, 1.12.2014, p. 49.

1

---
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.2385 Nitrogen dioxide analyzer. ( a ) *Identification.* The nitrogen dioxide analyzer is a device intended to measure the concentration of nitrogen dioxide in respiratory gas mixtures during administration of nitric oxide.
( b ) *Classification.* Class II (special controls). The device, when it is a standalone nitrogen dioxide analyzer and not those that are components of nitric oxide delivery systems intended to monitor nitrogen dioxide levels during inhaled nitric oxide therapy, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 868.9. The special control is FDA's “Guidance Document for Premarket Notification Submissions for Nitric Oxide Administration Apparatus, Nitric Oxide Analyzer, and Nitrogen Dioxide Analyzer.” See § 868.1(e) for the availability of this guidance document.
[65 FR 11465, Mar. 3, 2000, as amended at 84 FR 71811, Dec. 30, 2019]
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.1252 Percutaneous catheter for creation of an arteriovenous fistula for hemodialysis access. ( a ) *Identification.* This device is a single use percutaneous catheter system that creates an arteriovenous fistula in the arm of patients with chronic kidney disease who need hemodialysis.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Clinical performance testing must evaluate: ( i ) The ability to safely deliver, deploy, and remove the device;
( ii ) The ability of the device to create an arteriovenous fistula;
( iii ) The ability of the arteriovenous fistula to attain a blood flow rate and diameter suitable for hemodialysis;
( iv ) The ability of the fistula to be used for vascular access for hemodialysis;
( v ) The patency of the fistula; and
( vi ) The rates and types of all adverse events.
( 2 ) Animal testing must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be assessed: ( i ) Delivery, deployment, and retrieval of the device;
( ii ) Compatibility with other devices labeled for use with the device;
( iii ) Patency of the fistula;
( iv ) Characterization of blood flow at the time of the fistula creation procedure and at chronic followup; and
( v ) Gross pathology and histopathology assessing vascular injury and downstream embolization.
( 3 ) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested: ( i ) Simulated-use testing in a clinically relevant bench anatomic model to assess the delivery, deployment, activation, and retrieval of the device;
( ii ) Tensile strengths of joints and components;
( iii ) Accurate positioning and alignment of the device to achieve fistula creation; and
( iv ) Characterization and verification of all dimensions.
( 4 ) Electrical performance, electrical safety, and electromagnetic compatibility (EMC) testing must be performed for devices with electrical components.
( 5 ) Software verification, validation, and hazard analysis must be performed for devices that use software.
( 6 ) All patient-contacting components of the device must be demonstrated to be biocompatible.
( 7 ) Performance data must demonstrate the sterility of the device components intended to be provided sterile.
( 8 ) Performance data must support the shelf life of the device by demonstrating continued sterility, package integrity, and device functionality over the identified shelf life.
( 9 ) Labeling for the device must include: ( i ) Instructions for use;
( ii ) Identification of system components and compatible devices;
( iii ) Expertise needed for the safe use of the device;
( iv ) A detailed summary of the clinical testing conducted and the patient population studied; and
( v ) A shelf life and storage conditions.
[87 FR 9241, Feb. 18, 2022]
Editorial Note on Part 874
Editorial Note: Nomenclature changes to part 874 appear at 73 FR 35341, June 23, 2008.

§ 874.4760 Nasopharyngoscope (flexible or rigid) and accessories. ( a ) *Identification.* A nasopharyngoscope (flexible or rigid) and accessories is a tubular endoscopic device with any of a group of accessory devices which attach to the nasopharyngoscope and is intended to examine or treat the nasal cavity and nasal pharynx. It is typically used with a fiberoptic light source and carrier to provide illumination. The device is made of materials such as stainless steel and flexible plastic. This generic type of device includes the antroscope, nasopharyngolaryngoscope, nasosinuscope, nasoscope, postrhinoscope, rhinoscope, salpingoscope, flexible foreign body claw, flexible biopsy forceps, rigid biopsy curette, flexible biospy brush, rigid biopsy forceps and flexible biopsy curette, but excludes the fiberoptic light source and carrier.
( b ) *Classification.* Class II.
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.1455 Traumatic brain injury eye movement assessment aid. ( a ) *Identification.* A traumatic brain injury eye movement assessment aid is a prescription device that uses a patient's tracked eye movements to provide an interpretation of the functional condition of the patient's brain. This device is an assessment aid that is not intended for standalone detection or diagnostic purposes.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Clinical performance data under anticipated conditions of use must evaluate tracked eye movement in supporting the indications for use and include the following: ( i ) Evaluation of sensitivity, specificity, positive predictive value, and negative predictive value using a reference method of diagnosis;
( ii ) Evaluation of device test-retest reliability; and
( iii ) A description of the development of the reference method of diagnosis, which may include a normative database, to include the following: ( A ) A discussion of how the clinical work-up was completed to establish the reference method of diagnosis, including the establishment of inclusion and exclusion criteria; and
( B ) If using a normative database, a description of how the “normal” population was established, and the statistical methods and model assumptions used.
( 2 ) Software verification, validation, and hazard analysis must be performed. Software documentation must include a description of the algorithms used to generate device output.
( 3 ) Performance testing must demonstrate the electrical safety and electromagnetic compatibility (EMC) of the device.
( 4 ) The patient-contacting components of the device must be demonstrated to be biocompatible.
( 5 ) A light hazard assessment must be performed for all eye-tracking and visual display light sources.
( 6 ) Labeling must include: ( i ) A summary of clinical performance testing conducted with the device, including sensitivity, specificity, positive predictive value, negative predictive value, and test-retest reliability;
( ii ) A description of any normative database that includes the following: ( A ) The clinical definition used to establish a “normal” population and the specific selection criteria;
( B ) The format for reporting normal values;
( C ) Examples of screen displays and reports generated to provide the user results and normative data;
( D ) Statistical methods and model assumptions; and
( E ) Any adjustments for age and gender.
( iii ) A warning that the device should only be used by trained healthcare professionals;
( iv ) A warning that the device does not identify the presence or absence of traumatic brain injury or other clinical diagnoses;
( v ) A warning that the device is not a standalone diagnostic; and
( vi ) Any instructions to convey to patients regarding the administration of the test and collection of test data.
[86 FR 71384, Dec. 16, 2021]
Exhibit 31.1

CERTIFICATION

I, Corey
Henry, certify that:

1. I have reviewed this report on Form 10-K and all reports on Form 10-D required to be filed in respect of the period covered by this report on Form 10-K of Santander Drive Auto Receivables Trust 2015-4
(the Exchange Act periodic reports);

2. Based on my knowledge, the Exchange Act periodic reports, taken as a whole, do not
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;

3. Based on my knowledge, all of the distribution, servicing and other information required to be provided under Form 10-D for the period covered by this report is included in the Exchange Act periodic reports;

4. Based on
my knowledge and the servicer compliance statements required in this report under Item 1123 of Regulation AB, and except as disclosed in the Exchange Act periodic reports, the servicers have fulfilled their obligations under the servicing agreements
in all material respects; and

5. All of the reports on assessment of compliance with servicing criteria for asset-backed securities and
their related attestation reports on assessment of compliance with servicing criteria for asset-backed securities required to be included in this report in accordance with Item 1122 of Regulation AB and Exchange Act Rules 13a-18 and 15d-18 have been included as an exhibit to this report, except as otherwise disclosed in this report. Any material instances of noncompliance described in such
reports have been disclosed in this report on Form 10-K.

In giving the certifications above, I
have reasonably relied on information provided to me by the following unaffiliated parties: Wells Fargo Bank, National Association.



By:

/s/ Corey HenryName:

Corey HenryTitle:

President and Chief Executive OfficerSantander Drive Auto Receivables LLC, as Depositor(senior officer in charge of securitization ofthe depositor)Date:

March 30, 2018
§ 876.5140 Urethral insert with pump for bladder drainage. ( a ) *Identification.* A urethral insert with pump for bladder drainage is a catheter-like device with internal pump mechanism that is placed in the urethra. Under patient control the internal pump draws urine out of the bladder when voiding is desired, and blocks urine flow when continence is desired. The device is intended for use by women who cannot empty their bladder due to impaired detrusor contractility.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) The elements of the device that may contact the urinary tract must be demonstrated to be biocompatible.
( 2 ) Performance data must demonstrate the sterility of the device components that contact the urinary tract.
( 3 ) Performance data must support shelf life by demonstrating continued sterility of the device (or the sterile components), package integrity, and device functionality over the requested shelf life.
( 4 ) Non-clinical testing data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested: ( i ) Urine flow rate testing.
( ii ) Valve integrity testing.
( iii ) Bladder neck retention force testing.
( iv ) Pump/valve endurance testing.
( v ) Encrustation testing.
( vi ) Remote control reliability, mechanical integrity, and battery life testing.
( 5 ) Clinical testing must demonstrate safe and effective use, document the device acceptance rate and the adverse event profile associated with clinical use, and demonstrate that the device performs as intended under anticipated conditions of use.
( 6 ) Labeling must include: ( i ) Specific instructions, contraindications, warnings, cautions, limitations, and the clinical training needed for the safe use of the device.
( ii ) Statement of the maximum insert indwelling period.
( iii ) Information on the patient education and support program prior to and during initial device use.
( iv ) Information on the patient population for which the device has been demonstrated to be safe and effective.
( v ) Information on how the device operates and the recommended treatment regimen.
( vi ) A detailed summary of the device- and procedure-related complications or adverse events pertinent to use of the device.
( vii ) An expiration date/shelf life.
( 7 ) Patient labeling must be provided and must include: ( i ) Relevant contraindications, warnings, precautions, and adverse events/complications.
( ii ) Information on how the device operates and the recommended treatment regimen.
( iii ) Information on the patient education and support program prior to and during initial device use.
( iv ) Information on the patient population for which there is clinical evidence of safety and effectiveness.
( v ) The potential risks and benefits associated with the use of the device.
( vi ) Post-insertion care instructions.
( vii ) Alternative treatments.
[80 FR 18309, Apr. 6, 2015]